About to double, page-6

Excellent presentation. Thanks for posting it. Graeme Carson gives an overview of Corum's current position, looks at growth prospects which can bring improved margins with it, risks, barriers to competition and integration of the PharmX business. Corum with a current market share of only about 20% of the pharmacy SAAS business has the opportunity to penetrate further in particular with the corporate pharmacy groups with it new software which is ideally suited to group management systems and analytics. The improved cash position and improved cash flow supports further fine tuning of the software offerings and marketing. Graeme however fails to mention the potential for Corum technology to be applied to other retail sectors that could take the company outside of the tightly contained structure of pharmacy business.

With Corum to be reporting its 4c Quarterly by the end of April and the again in June, the market will be getting valuable feedback which could underpin growing confidence in Corum's new management team and future prospects.